Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Hybrid Pharma LLC
483
•Hybrid Pharma LLC•June 20, 2019

Hybrid Pharma LLC – FDA 483, Jun 20, 2019

Record Details

An FDA inspection conducted at Hybrid Pharma LLC, an outsourcing facility located in Deerfield Beach, FL, from May 20 to June 20, 2019, identified significant deficiencies in manufacturing practices. The FDA 483 report detailed numerous observations related to inadequate controls and procedures, crucial for ensuring drug product quality and sterility. Key violations included a lack of adequate validation for aseptic and sterilization processes, such as media fills failing to simulate worst-case conditions and the absence of endotoxin testing for intrathecal drug products. Environmental controls were also found deficient, with brown discoloration on HEPA filters and cleanroom walls, and ineffective cleaning efficacy studies. The facility also exhibited poor environmental monitoring, non-cleanable surfaces, and loose ceiling tiles in critical areas. Furthermore, the company lacked essential written procedures for production and process controls, leading to unvalidated drug product formulations and sterilization parameters. Laboratory records were incomplete, showing inadequately validated test methods and missing data for routine product release. The stability program was deficient, with no formal plan and reliance on trial batches for stability studies. Critical issues were also noted regarding quality control unit responsibilities not being formalized or followed, and a widespread lack of documented employee training for various functions, including visual inspection and GMP. Finally, drug product labels were found to be non-compliant, repeatedly missing the required "This is a compounded drug" statement. These observations indicate a failure to adhere to good manufacturing practices for sterile drug production. Hybrid Pharma LLC is required to address these findings and implement comprehensive corrective actions to ensure compliance and patient safety.

Company
Hybrid Pharma LLC
Inspection date
June 20, 2019
Office
Atlanta District Office
Person
  • Bonita S. Chester (Director of Inspection Readiness)
View Company Profile

ID · 789b58b7-aef6-4f74-8417-631b43204e12

Violation Codes6
FD&C Act 905(j)21 CFR 21021 CFR 211FD&C Act 801(a)(3)21 CFR 331(c)21 U.S.C. 324(a)(4)

Full citation text and observation details available on the Dashboard.

Other documents for Hybrid Pharma LLC
  • 483 - 2023-11-09November 9, 2023

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Hybrid Pharma LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.